Portfolio
3
companies
Unify
Unify offers a single interface to test and deploy large language models across various providers.
Webiny
Webiny develops an open-source framework that helps engineers build and deploy serverless applications.
Huma Therapeutics
Huma Therapeutics develops a modular digital health platform for virtual hospital care and decentralized clinical trials.
Jonathan Machado
Senior Investment Director of Samsung Next
Jonathan brings venture capital and legal experience from roles including Venture Partner at AI Futures Fund and Senior Investment Director at Samsung Next.
LinkedIn
Andy Duong
investor
Andy works as an investor at Samsung Next Ventures, with experience across companies including Protect AI, Perplexity, and Liquid AI.
LinkedInThe funding round was backed by participants including Y Combinator, A Capital, and SignalFire.
"The world is missing out on a lot of AI’s potential because it’s too slow, complex, and expensive to deploy. Unify is going to change that!"
The Y Combinator-backed open-source framework secured backing from M12, Samsung Next, Episode 1 and Cota Capital to scale its developer tooling.
"We see the mandate inside organisations to adopt serverless is coming from the top. The technical executives see serverless as a competitive advantage for their business. It’s the same market motion we saw several years ago when organisations moved from on-premise solutions to the cloud. This wasn’t a bottom up adoption, but rather a top-down approach. This same is now happening with serverless and it is our goal at Webiny to enable this new wave of infrastructure transformation."
The Series C financing was led by Leaps by Bayer and Hitachi Ventures to support international expansion and platform development.
"This is a pivotal moment in Huma’s development. We have exceptional partners and strategic investors who will support us in our mission to help people worldwide live longer and fuller lives. We’re already demonstrating how ‘hospital at home’ can transform healthcare, and how decentralized clinical trials can advance research in ways that weren’t imaginable even one year ago. Now we want to accelerate the pace of change and continue to innovate for better care and research worldwide."
